Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Males Clear all

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy Subjects, Cardiac Repolarization
Interventions: Placebo, ASP1941, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Alzheimer's Disease
Interventions: E2609; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: BI 207127 NA; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: BMS-986419 DR Capsule, BMS-986419 IR Tablet; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: GW856553; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Erectile Dysfunction
Interventions: avanafil, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Healthy
Interventions: [11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Renal Impairment
Interventions: Mezigdomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida

Conditions: Healthy Adults
Interventions: EC5026 oral tablet, Placebo oral tablet; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ascites Hepatic
Interventions: OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV, OsrHSA 140 mg/kg IV, OsrHSA 200 mg/kg IV, Placebo; Drug · Other
Lead sponsor: Healthgen Biotechnology Corp.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Renal Impairment, Renal Disease, Kidney Disease
Interventions: Nitazoxanide; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami Lakes, Florida • Orlando, Florida

Conditions: Diabetic Nephropathy
Interventions: CTP-499; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Kidney Failure, Chronic
Interventions: Lanthanum Carbonate, Sevelamer; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy, Enteric Hyperoxaluria
Interventions: FB-001, Placebo; Biological
Lead sponsor: Federation Bio Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: 5% Sildenafil Cream (SST-6006), Oral Sildenafil 50 mg; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy, Renal Impairment
Interventions: quinine sulfate; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy, Chronic Kidney Disease
Interventions: Diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Gout
Interventions: RDEA3170 10 mg, RDEA3170 2.5 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: COVID-19
Interventions: PF-07817883; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Tampa, Florida • Saint Paul, Minnesota

Conditions: West Nile Viral Infection
Interventions: HydroVax-001, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers, Enteric Hyperoxaluria
Interventions: NOV-001, NB1000S, NB2000P, Placebo; Combination Product · Biological · Drug
Lead sponsor: Novome Biotechnologies Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more

Search by objective public record fields.

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

Study Evaluating the Effects of Avanafil on Semen Parameters

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults

Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults

RDEA3170 Bioavailability Study

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

Phase 1 Trial of Inactivated West Nile Virus Vaccine

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects